This document discusses screening for atherosclerosis and the different perspectives on it from cardiac imaging experts, practicing physicians, patients, and academic professors. It also addresses the two key questions around screening: whether a screening strategy provides good value for the cost and if the healthcare budget can support providing it to patients. The document outlines clinical trials showing statin therapy for prevention can reduce deaths, heart attacks, procedures and costs over 5 years. However, widespread screening raises concerns about overburdening the healthcare system. Identifying high-risk patients for sudden cardiac death also presents a screening paradox in balancing potential benefits with large screening populations.
Testing your blood sugar before and after certain activities using the ACCU-CHEK Testing in Pairs tool can help people with diabetes see how everyday actions like going to the mailbox affect their blood sugar levels. The free paper tool encourages testing blood sugar before and after a meal, exercise, or other routine over the course of a week to discover personalized insights into managing diabetes.
Stuart Reid - When Passion Obscures the Facts:The Case For Evidence-Based Te...TEST Huddle
EuroSTAR Software Testing Conference 2010 presentation on When Passion Obscures the Facts:The Case For Evidence-Based Testing by Stuart Reid. See more at: http://conference.eurostarsoftwaretesting.com/past-presentations/
AAA 2016 networking day final presentationsMike Harris
The document summarizes the results and updates from the NHS AAA Screening Programme. Some key points:
- Almost 1.3 million men were invited for screening, with an uptake of 79.5%
- Nearly 13,000 abdominal aortic aneurysms (AAA) larger than 3cm were detected, with a prevalence of 1.3%
- Options to extend surveillance intervals to biennially were presented, which could result in cost savings of over £600,000 per invited cohort.
- Evidence was presented on the risk of AAA progression in men with subaneurysmal aortas between 2.6-2.9cm, supporting potential rescreening of these men after 5 years.
Simvastatin in Aneurysmal Subarachnoid Hemorrhage (SASH) Trial is a prospective, randomized, double-blind, placebo-controlled pilot trial that assessed the role of simvastatin in preventing vasospasm and improving outcomes in patients with aneurysmal subarachnoid hemorrhage. The trial randomized 38 patients to receive either simvastatin 80mg or placebo for 14 days after aneurysm clipping. Results showed lower rates of vasospasm, neurological deterioration and mortality in the simvastatin group, though differences were not statistically significant. Larger multicenter trials are still needed to definitively determine if statins provide clinical benefits for aneurysmal subarachnoid hemorrhage
1. Ultrasound guidance for transradial artery access significantly improves accuracy and reduces time to access compared to palpation alone.
2. Ultrasound guidance decreases difficult access procedures and reduces the need to crossover to a different technique or vascular access site.
3. A study of 1000 consecutive transradial procedures using ultrasound guidance found a crossover rate of less than 1%, demonstrating that low and predictable crossover rates are attainable with ultrasound.
- Acute kidney injury (AKI) is a common and serious problem in hospitalized patients, especially those in the ICU, with mortality rates over 50% in dialyzed ICU patients.
- The RIFLE and AKIN classification systems provide criteria for staging AKI severity based on changes in serum creatinine and urine output.
- Biomarkers like NGAL and IL-18 allow for earlier diagnosis of AKI than serum creatinine, detecting injury within hours compared to the days it takes creatinine levels to rise. Promising biomarkers indicate proximal tubule injury.
- While supportive care remains the primary treatment, new anticoagulants and agents targeting apoptosis, inflammation and
This document discusses screening for atherosclerosis and the different perspectives on it from cardiac imaging experts, practicing physicians, patients, and academic professors. It also addresses the two key questions around screening: whether a screening strategy provides good value for the cost and if the healthcare budget can support providing it to patients. The document outlines clinical trials showing statin therapy for prevention can reduce deaths, heart attacks, procedures and costs over 5 years. However, widespread screening raises concerns about overburdening the healthcare system. Identifying high-risk patients for sudden cardiac death also presents a screening paradox in balancing potential benefits with large screening populations.
Testing your blood sugar before and after certain activities using the ACCU-CHEK Testing in Pairs tool can help people with diabetes see how everyday actions like going to the mailbox affect their blood sugar levels. The free paper tool encourages testing blood sugar before and after a meal, exercise, or other routine over the course of a week to discover personalized insights into managing diabetes.
Stuart Reid - When Passion Obscures the Facts:The Case For Evidence-Based Te...TEST Huddle
EuroSTAR Software Testing Conference 2010 presentation on When Passion Obscures the Facts:The Case For Evidence-Based Testing by Stuart Reid. See more at: http://conference.eurostarsoftwaretesting.com/past-presentations/
AAA 2016 networking day final presentationsMike Harris
The document summarizes the results and updates from the NHS AAA Screening Programme. Some key points:
- Almost 1.3 million men were invited for screening, with an uptake of 79.5%
- Nearly 13,000 abdominal aortic aneurysms (AAA) larger than 3cm were detected, with a prevalence of 1.3%
- Options to extend surveillance intervals to biennially were presented, which could result in cost savings of over £600,000 per invited cohort.
- Evidence was presented on the risk of AAA progression in men with subaneurysmal aortas between 2.6-2.9cm, supporting potential rescreening of these men after 5 years.
Simvastatin in Aneurysmal Subarachnoid Hemorrhage (SASH) Trial is a prospective, randomized, double-blind, placebo-controlled pilot trial that assessed the role of simvastatin in preventing vasospasm and improving outcomes in patients with aneurysmal subarachnoid hemorrhage. The trial randomized 38 patients to receive either simvastatin 80mg or placebo for 14 days after aneurysm clipping. Results showed lower rates of vasospasm, neurological deterioration and mortality in the simvastatin group, though differences were not statistically significant. Larger multicenter trials are still needed to definitively determine if statins provide clinical benefits for aneurysmal subarachnoid hemorrhage
1. Ultrasound guidance for transradial artery access significantly improves accuracy and reduces time to access compared to palpation alone.
2. Ultrasound guidance decreases difficult access procedures and reduces the need to crossover to a different technique or vascular access site.
3. A study of 1000 consecutive transradial procedures using ultrasound guidance found a crossover rate of less than 1%, demonstrating that low and predictable crossover rates are attainable with ultrasound.
- Acute kidney injury (AKI) is a common and serious problem in hospitalized patients, especially those in the ICU, with mortality rates over 50% in dialyzed ICU patients.
- The RIFLE and AKIN classification systems provide criteria for staging AKI severity based on changes in serum creatinine and urine output.
- Biomarkers like NGAL and IL-18 allow for earlier diagnosis of AKI than serum creatinine, detecting injury within hours compared to the days it takes creatinine levels to rise. Promising biomarkers indicate proximal tubule injury.
- While supportive care remains the primary treatment, new anticoagulants and agents targeting apoptosis, inflammation and
This document summarizes a study evaluating the utility of using multiplex panels of biomarkers for screening purposes without prior knowledge of biomarkers of interest. Fifteen multiplex panels were developed containing up to ten assays each, requiring less than 1 mL of sample to measure 122 biomarkers total. Assays showed low cross-reactivity, broad dynamic ranges, and good reproducibility. The multiplex panels allowed rapid screening and stratification of patient populations to identify potential biomarker targets.
SIMVASTATIN IN ANEURYSMAL SUBARACHNOID HEAMORRHAGE (SASH) TRIAL Sumit2018
This document describes the SASH trial, a prospective randomized double-blind placebo-controlled pilot study that assessed the role of simvastatin in preventing vasospasm and improving outcomes in patients with aneurysmal subarachnoid hemorrhage (SAH). The study found lower rates of vasospasm, neurological deterioration, and mortality in the simvastatin group compared to placebo, though the differences were not statistically significant due to the small sample size. The document concludes that while statins may provide benefits, larger phase III studies are still needed to definitively determine if statins improve outcomes for SAH patients.
This document discusses standardizing marker values in first trimester screening to account for factors like gestational age, weight, and ethnicity. It explains that marker levels depend on various characteristics, so converting to multiples of the median (MoM) removes these effects. Any biases or errors in determining gestational age from crown-rump length can significantly impact the standardized MoM values and affect screening accuracy, leading to changes in detection and false positive rates. Precise measurement of crown-rump length is important for obtaining accurate gestational dating and standardizing marker levels.
The document discusses local initiatives to establish exercise programmes for cancer patients. A physiotherapist established a study using a Wii Fitness program with haematology patients. Results found improved mood, motivation, and physical activity levels. Based on this success, a permanent Technical Instructor post was established to monitor programmes. Further initiatives included cancer rehabilitation programmes and promoting exercise through various means. The initiatives aim to improve cancer patients' quality of life and outcomes through exercise during and after treatment.
Training load and injuries in football- lessons from research and practiseTorstein Dalen-Lorentsen
This document summarizes research on training load management in football. It discusses how monitoring training load and analyzing the data can inform decision making to find the optimal load for each player. While acute:chronic workload ratios are often used, the evidence for their ability to prevent injuries is limited due to poor study quality and lack of randomized controlled trials. Training load must be considered together with other individual factors, and load management aims to balance training and recovery rather than precisely predict or prevent health problems.
This is Dr. Mike Young's presentation from the 2016 Child to Champion Conference on Velocity Based Training. In this lecture, Dr. Young presented the drawbacks of traditional mass-based loading and discussed the potential benefits of using velocity based metrics such as average and peak velocity and power in the training of athletes. Mike also provides insight in to successful use of sport technology to increase compliance and usability.
Point of care testing (POCT) is one of the fastest growing areas of clinical laboratory medicine. It is growing at a higher rate than conventional laboratory testing. POCT refers to tests performed outside of clinical laboratories, near the patient, without requiring dedicated space. It provides rapid and simple tests using small sample volumes. However, POCT also presents challenges as it is performed by clinical staff instead of laboratory trained individuals, increasing risks of errors. Proper management and oversight is needed to ensure quality control and compliance with regulatory standards for POCT.
The document summarizes results from the National Abdominal Aortic Aneurysm Screening Programme in England. Over 1.5 million men were screened, with over 18,000 large AAAs detected. Nearly 14,000 men are in surveillance and over 3,400 men have been treated. The programme is optimizing to reduce surveillance intervals and improve uptake. Research is ongoing on quality of life for men in surveillance and outcomes for those with subaneurysmal aortas. Draft NICE guidelines recommend screening and surveillance protocols. The future of the programme involves monitoring these changes and improving care for men identified.
The document summarizes a marketing strategy used by Gambro to promote continuous renal replacement therapy (CRRT) for acute kidney injury treatment. The strategy included conducting research on nephrologists' preferences, creating an educational website called CRRTcounts.com, developing content like videos and articles, and implementing tracking of website engagement. The goal was to increase awareness of CRRT and provide clinical evidence to support its use over other therapies.
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018hivlifeinfo
Expert faculty summarize key NAFLD/NASH studies from this important annual conference. Use these slides to review data on noninvasive screening, clinical outcomes, emerging treatments.
Ira M. Jacobson, MD
Philip N. Newsome, PhD, FRCPE
Format: Microsoft PowerPoint (.ppt)
File Size: 421 KB
Released: December 3, 2018
This document provides a summary of the national abdominal aortic aneurysm (AAA) screening programme in the UK, including key statistics and performance indicators for 2017/2018. It discusses several initiatives to improve the programme, such as adopting a new demographic data source, developing an inequalities toolkit, updating training resources, and establishing image quality standards. The document outlines plans to test a proposed 10-point image scoring system to help standardize the assessment of ultrasound image quality across the screening programme.
1. The document discusses whether prostate cancer screening should be recommended for elderly men over age 65 given the high prevalence of prostate cancer but also the slow growing nature in many cases and short life expectancy.
2. While screening can detect cancer early, it also risks overdiagnosing biologically unimportant cancers and subjects men to potential harms of treatment without clear benefits due to their age.
3. Guidelines in the US have differing recommendations regarding screening older men, reflecting the ongoing debate around the balance of risks and benefits in this population.
1. The document discusses the debate around prostate cancer screening in elderly men over age 65, with arguments on both sides.
2. Screening may detect cancers early that would not have progressed or caused harm in a man's lifetime given his life expectancy. However, screening also risks overdiagnosis and overtreatment of biologically unimportant cancers.
3. Guidelines in the US do not recommend routine screening for low-risk, elderly patients due to the scientific uncertainties around the balance of benefits and harms. Patient-clinician discussion is important to make informed, individual decisions.
1. The document discusses various clinical and pathological factors that can help predict outcomes for prostate cancer patients undergoing surgery, such as cancer volume, Gleason grade, clinical stage, and PSA levels.
2. Nomograms and statistical models have been developed using these factors to predict chances of cancer recurrence, pathologic stage, and disease progression.
3. However, some factors like clinical stage may have limited predictive value. Ongoing research aims to improve predictive accuracy by addressing issues like PSA standardization and biopsy upgrading.
AAA screening national programme update September 2019: Lisa SummersPHEScreening
This document provides a national update on the AAA screening programme in the UK. It discusses updates to clinical leads, screening figures, key performance indicators, standards and guidance, IT systems, equipment evaluation, rationale for modifying surveillance intervals, and initiatives across the four nations and to address inequalities in screening.
This document discusses prostate specific antigen (PSA) and its clinical uses. It provides information on:
- What PSA is and how it is produced by the prostate
- How PSA levels are measured and can be affected by various factors
- How PSA is used for screening, diagnosis, staging of prostate cancer
- How PSA levels after treatment can provide prognostic information and indicate recurrence
- The limitations and controversies around PSA screening
A unified database of structure/activity data is presented. This database was used to derive activity / classification models with Bayesian statistics and Linear Discriminant Analysis. This work has been published: http://www.nature.com/nbt/journal/v24/n7/abs/nbt1228.html
1. Artificial intelligence techniques like machine learning can be used to analyze multiple variables from medical imaging data and clinical records to make predictions.
2. Studies have shown that combining functional imaging parameters, clinical factors, and texture features using support vector machines or neural networks can improve prediction of diseases like cancer compared to individual readings.
3. With the trend of large multi-parametric datasets from PET/MR imaging, applying statistical machine learning approaches to integrated image "big data" could further enhance diagnostic performance for conditions like predicting tumor response to treatments.
2017 02-10-slas-washington dc-combinations-sig-ht-combinations-erictangOliver Leven
- High-throughput screening of drug combinations across 240 cancer cell lines identified synergistic combinations that enhanced cell killing compared to single agents.
- Combination profiles were analyzed within and across disease types to identify opportunities for patient segmentation and indications. Challenges include the large matrix size, lack of clinical safety data, and integrating genetic biomarkers.
- Validation in patient-derived tumour cells and 3D cultures can prioritize the most synergistic combinations for driving in vivo and clinical studies to improve personalized cancer treatment.
This document discusses the high-level operations of the clinical pathology laboratory at Changi General Hospital. It provides statistics on the hospital and increasing patient load. It also describes the laboratory's efforts to improve workflow challenges and ensure fast and accurate test turnaround times. This is achieved through streamlining pre-analytics, analytics, and post-analytics processes. Specifically, the laboratory focuses on batching and automation, stat test prioritization, extensive quality control, and automatic result verification to provide quality patient care.
NHS screening leaflet short urls and qr codes PDFPHEScreening
This document provides short URLs and QR codes for digital information leaflets about various NHS screening programs in the UK, including antenatal and newborn, AAA, bowel cancer, breast cancer, cervical cancer, and diabetic eye screening. Short URLs and QR codes are included to easily direct people to online collections of digital information leaflets for each screening program through mobile devices.
NHS screening leaflet short urls and qr codesPHEScreening
This document provides short URLs and QR codes for digital information leaflets about various NHS screening programs in the UK, including antenatal and newborn, AAA, bowel cancer, breast cancer, cervical cancer, and diabetic eye screening. Short URLs and QR codes are included to easily direct people to online collections of digital information leaflets for each screening program through mobile devices.
This document summarizes a study evaluating the utility of using multiplex panels of biomarkers for screening purposes without prior knowledge of biomarkers of interest. Fifteen multiplex panels were developed containing up to ten assays each, requiring less than 1 mL of sample to measure 122 biomarkers total. Assays showed low cross-reactivity, broad dynamic ranges, and good reproducibility. The multiplex panels allowed rapid screening and stratification of patient populations to identify potential biomarker targets.
SIMVASTATIN IN ANEURYSMAL SUBARACHNOID HEAMORRHAGE (SASH) TRIAL Sumit2018
This document describes the SASH trial, a prospective randomized double-blind placebo-controlled pilot study that assessed the role of simvastatin in preventing vasospasm and improving outcomes in patients with aneurysmal subarachnoid hemorrhage (SAH). The study found lower rates of vasospasm, neurological deterioration, and mortality in the simvastatin group compared to placebo, though the differences were not statistically significant due to the small sample size. The document concludes that while statins may provide benefits, larger phase III studies are still needed to definitively determine if statins improve outcomes for SAH patients.
This document discusses standardizing marker values in first trimester screening to account for factors like gestational age, weight, and ethnicity. It explains that marker levels depend on various characteristics, so converting to multiples of the median (MoM) removes these effects. Any biases or errors in determining gestational age from crown-rump length can significantly impact the standardized MoM values and affect screening accuracy, leading to changes in detection and false positive rates. Precise measurement of crown-rump length is important for obtaining accurate gestational dating and standardizing marker levels.
The document discusses local initiatives to establish exercise programmes for cancer patients. A physiotherapist established a study using a Wii Fitness program with haematology patients. Results found improved mood, motivation, and physical activity levels. Based on this success, a permanent Technical Instructor post was established to monitor programmes. Further initiatives included cancer rehabilitation programmes and promoting exercise through various means. The initiatives aim to improve cancer patients' quality of life and outcomes through exercise during and after treatment.
Training load and injuries in football- lessons from research and practiseTorstein Dalen-Lorentsen
This document summarizes research on training load management in football. It discusses how monitoring training load and analyzing the data can inform decision making to find the optimal load for each player. While acute:chronic workload ratios are often used, the evidence for their ability to prevent injuries is limited due to poor study quality and lack of randomized controlled trials. Training load must be considered together with other individual factors, and load management aims to balance training and recovery rather than precisely predict or prevent health problems.
This is Dr. Mike Young's presentation from the 2016 Child to Champion Conference on Velocity Based Training. In this lecture, Dr. Young presented the drawbacks of traditional mass-based loading and discussed the potential benefits of using velocity based metrics such as average and peak velocity and power in the training of athletes. Mike also provides insight in to successful use of sport technology to increase compliance and usability.
Point of care testing (POCT) is one of the fastest growing areas of clinical laboratory medicine. It is growing at a higher rate than conventional laboratory testing. POCT refers to tests performed outside of clinical laboratories, near the patient, without requiring dedicated space. It provides rapid and simple tests using small sample volumes. However, POCT also presents challenges as it is performed by clinical staff instead of laboratory trained individuals, increasing risks of errors. Proper management and oversight is needed to ensure quality control and compliance with regulatory standards for POCT.
The document summarizes results from the National Abdominal Aortic Aneurysm Screening Programme in England. Over 1.5 million men were screened, with over 18,000 large AAAs detected. Nearly 14,000 men are in surveillance and over 3,400 men have been treated. The programme is optimizing to reduce surveillance intervals and improve uptake. Research is ongoing on quality of life for men in surveillance and outcomes for those with subaneurysmal aortas. Draft NICE guidelines recommend screening and surveillance protocols. The future of the programme involves monitoring these changes and improving care for men identified.
The document summarizes a marketing strategy used by Gambro to promote continuous renal replacement therapy (CRRT) for acute kidney injury treatment. The strategy included conducting research on nephrologists' preferences, creating an educational website called CRRTcounts.com, developing content like videos and articles, and implementing tracking of website engagement. The goal was to increase awareness of CRRT and provide clinical evidence to support its use over other therapies.
Clinical Impact of New NAFLD/NASH Data From San Francisco 2018hivlifeinfo
Expert faculty summarize key NAFLD/NASH studies from this important annual conference. Use these slides to review data on noninvasive screening, clinical outcomes, emerging treatments.
Ira M. Jacobson, MD
Philip N. Newsome, PhD, FRCPE
Format: Microsoft PowerPoint (.ppt)
File Size: 421 KB
Released: December 3, 2018
This document provides a summary of the national abdominal aortic aneurysm (AAA) screening programme in the UK, including key statistics and performance indicators for 2017/2018. It discusses several initiatives to improve the programme, such as adopting a new demographic data source, developing an inequalities toolkit, updating training resources, and establishing image quality standards. The document outlines plans to test a proposed 10-point image scoring system to help standardize the assessment of ultrasound image quality across the screening programme.
1. The document discusses whether prostate cancer screening should be recommended for elderly men over age 65 given the high prevalence of prostate cancer but also the slow growing nature in many cases and short life expectancy.
2. While screening can detect cancer early, it also risks overdiagnosing biologically unimportant cancers and subjects men to potential harms of treatment without clear benefits due to their age.
3. Guidelines in the US have differing recommendations regarding screening older men, reflecting the ongoing debate around the balance of risks and benefits in this population.
1. The document discusses the debate around prostate cancer screening in elderly men over age 65, with arguments on both sides.
2. Screening may detect cancers early that would not have progressed or caused harm in a man's lifetime given his life expectancy. However, screening also risks overdiagnosis and overtreatment of biologically unimportant cancers.
3. Guidelines in the US do not recommend routine screening for low-risk, elderly patients due to the scientific uncertainties around the balance of benefits and harms. Patient-clinician discussion is important to make informed, individual decisions.
1. The document discusses various clinical and pathological factors that can help predict outcomes for prostate cancer patients undergoing surgery, such as cancer volume, Gleason grade, clinical stage, and PSA levels.
2. Nomograms and statistical models have been developed using these factors to predict chances of cancer recurrence, pathologic stage, and disease progression.
3. However, some factors like clinical stage may have limited predictive value. Ongoing research aims to improve predictive accuracy by addressing issues like PSA standardization and biopsy upgrading.
AAA screening national programme update September 2019: Lisa SummersPHEScreening
This document provides a national update on the AAA screening programme in the UK. It discusses updates to clinical leads, screening figures, key performance indicators, standards and guidance, IT systems, equipment evaluation, rationale for modifying surveillance intervals, and initiatives across the four nations and to address inequalities in screening.
This document discusses prostate specific antigen (PSA) and its clinical uses. It provides information on:
- What PSA is and how it is produced by the prostate
- How PSA levels are measured and can be affected by various factors
- How PSA is used for screening, diagnosis, staging of prostate cancer
- How PSA levels after treatment can provide prognostic information and indicate recurrence
- The limitations and controversies around PSA screening
A unified database of structure/activity data is presented. This database was used to derive activity / classification models with Bayesian statistics and Linear Discriminant Analysis. This work has been published: http://www.nature.com/nbt/journal/v24/n7/abs/nbt1228.html
1. Artificial intelligence techniques like machine learning can be used to analyze multiple variables from medical imaging data and clinical records to make predictions.
2. Studies have shown that combining functional imaging parameters, clinical factors, and texture features using support vector machines or neural networks can improve prediction of diseases like cancer compared to individual readings.
3. With the trend of large multi-parametric datasets from PET/MR imaging, applying statistical machine learning approaches to integrated image "big data" could further enhance diagnostic performance for conditions like predicting tumor response to treatments.
2017 02-10-slas-washington dc-combinations-sig-ht-combinations-erictangOliver Leven
- High-throughput screening of drug combinations across 240 cancer cell lines identified synergistic combinations that enhanced cell killing compared to single agents.
- Combination profiles were analyzed within and across disease types to identify opportunities for patient segmentation and indications. Challenges include the large matrix size, lack of clinical safety data, and integrating genetic biomarkers.
- Validation in patient-derived tumour cells and 3D cultures can prioritize the most synergistic combinations for driving in vivo and clinical studies to improve personalized cancer treatment.
This document discusses the high-level operations of the clinical pathology laboratory at Changi General Hospital. It provides statistics on the hospital and increasing patient load. It also describes the laboratory's efforts to improve workflow challenges and ensure fast and accurate test turnaround times. This is achieved through streamlining pre-analytics, analytics, and post-analytics processes. Specifically, the laboratory focuses on batching and automation, stat test prioritization, extensive quality control, and automatic result verification to provide quality patient care.
NHS screening leaflet short urls and qr codes PDFPHEScreening
This document provides short URLs and QR codes for digital information leaflets about various NHS screening programs in the UK, including antenatal and newborn, AAA, bowel cancer, breast cancer, cervical cancer, and diabetic eye screening. Short URLs and QR codes are included to easily direct people to online collections of digital information leaflets for each screening program through mobile devices.
NHS screening leaflet short urls and qr codesPHEScreening
This document provides short URLs and QR codes for digital information leaflets about various NHS screening programs in the UK, including antenatal and newborn, AAA, bowel cancer, breast cancer, cervical cancer, and diabetic eye screening. Short URLs and QR codes are included to easily direct people to online collections of digital information leaflets for each screening program through mobile devices.
PHE screening inequalities conference final slidesPHEScreening
This document outlines plans for a conference on addressing inequalities in screening. The aims of the conference are to share information on actions being taken to tackle inequalities, seek expert input on further steps, and discuss successes and new learning. The document provides background on PHE's screening inequalities strategy, examples of data showing inequalities, and initiatives underway like the FIT screening implementation and health equity audit toolkit. Speakers will discuss evidence-based practices to address inequalities including effective invitee interventions and potential program-level changes. The final section covers accessing screening data to support inequalities work while complying with information governance.
1) The document discusses health inequalities and screening inequalities, noting that uptake rates tend to be lower for those in more deprived socioeconomic groups and for certain minority populations.
2) It provides an overview of the Public Health England's Screening Division Inequalities Strategy, which aims to increase uptake in the most deprived areas by 10% by addressing barriers to screening.
3) The strategy involves tools to help services analyze uptake data and identify groups with lower participation, as well as guidance on improving access for populations such as those with severe mental illness.
The document discusses health inequalities in cancer screening programs. It aims to familiarize screening technicians with health inequalities, update them on initiatives to address inequalities from the UK Public Health England screening division, and explore further actions that could be taken. It notes that screening inequalities exist for groups experiencing economic deprivation, minority ethnic groups, people with disabilities, and other protected groups. Addressing inequalities requires understanding differences in participation within and between screening programs and targeting groups at higher risk who are less likely to participate. Actions discussed include analyzing screening data to identify inequalities, making programs more accessible, and establishing collaboration groups to share information.
1) The document discusses health inequalities in cancer screening programs. It notes that uptake rates tend to be lower for populations experiencing economic deprivation, belonging to minority ethnic groups, or having disabilities.
2) Data is presented showing gaps in life expectancy between deprived and affluent areas of up to 9 years for males. Screening coverage and outcomes also tend to be lower for disadvantaged groups.
3) Actions are proposed to improve accessibility of screening for people with disabilities or severe mental illness through targeted outreach and accommodations. Establishing collaborations through online platforms and sharing work at program board meetings is encouraged.
This document discusses health inequalities and screening inequalities. It aims to refresh knowledge on health inequalities, update on the Public Health England screening division's inequalities strategy, and explore actions screening nurses can take to tackle inequalities. It provides data showing screening uptake disparities based on factors like learning disabilities, ethnicity, and socioeconomic status. It also outlines guidance and tools to help screening services increase uptake in deprived areas and make screening more accessible for groups facing inequalities.
AAA Screening : Extending the screener rolePHEScreening
This document describes extending the role of screening technicians in an abdominal aortic aneurysm (AAA) screening program to include basic physical health checks. It provides details on the current and proposed screening models, including the additional training and guidance technicians receive to take blood pressure and seek nurse advice. An example is given of how a high blood pressure reading was identified during screening and subsequently treated, benefiting both the patient and their GP. Feedback from patients and GPs is positive about the expanded technician role in detecting other health issues alongside AAA screening.
AAA Screening : Extending the screener role for nursesPHEScreening
The document discusses extending the role of screening technicians in an abdominal aortic aneurysm (AAA) screening program to include basic physical health checks. The program saw a decline in eligible men for screening over time as the population grew. The extended screener role would have technicians take basic observations like blood pressure and seek nurse practitioner advice if needed. Patients would receive education materials and follow up calls. Nurses would conduct further assessments over the phone. The changes aim to catch other health issues and assure quality through training, audits, and patient and doctor feedback. The feedback received has been positive.
Improving outcomes of patients on AAA surveillance Adam HaquePHEScreening
This document discusses improving outcomes for patients undergoing abdominal aortic aneurysm (AAA) surveillance through exercise interventions. It presents evidence that cardiovascular fitness, as measured by cardiopulmonary exercise testing (CPET), is a key determinant of outcomes for AAA patients. A trial is proposed to evaluate the effects of a 24-week patient-directed exercise program on CPET measures of fitness for AAA surveillance patients compared to standard advice. The goal is to determine if objective measures of cardiovascular fitness can be improved through a scalable and deliverable exercise program to provide benefits like reduced peri-operative risk and improved survival for AAA patients.
AAA nurses training: programme boards presentation September 2019PHEScreening
This document discusses programme boards for screening quality assurance. It notes that nurses rarely attend all programme boards due to small team sizes and priority being given to patient assessments. Programme boards ensure screening programmes meet national standards and involve multiple stakeholder organizations. They discuss performance against quality standards, learning from incidents, and service improvement initiatives. The most discussed topics include performance metrics, incidents and lessons learned, quality assurance visit outcomes, and risks/mitigation plans. Nursing contributions could involve audits on access, uptake, and waiting times. Key messages from boards should be communicated to nursing teams.
AAA screeners LGBT awareness training September 2019PHEScreening
The document discusses LGBTQ+ awareness in abdominal aortic aneurysm screening programs, including definitions of key terms like sexual orientation, gender identity, and pronouns. It also notes potential health inequalities faced by LGBTQ+ people and how current AAA screening procedures and invitations may need improvements to be more inclusive of transgender and non-binary individuals.
Digital screening information event 2 October 2019PHEScreening
Slides from the event for antenatal screening co-ordinators in Birmingham on 2 October 2019 to discuss the plans for moving to digital screening information.
NHS Breast Screening Programme & Association of Breast Surgery AuditPHEScreening
The document describes the NHS Breast Screening Programme (NHSBSP) and Association of Breast Surgery (ABS) audit. The audit compares surgical data to quality assurance standards to assess performance. It analyzes data on all breast cancers detected through screening in the UK each year. The annual audit has three parts - the main audit examines the most recent year's data, the adjuvant audit examines treatment data from the prior year, and the survival audit examines 5-year survival rates. The document provides guidance on extracting data from the NBSS database system, checking the data for errors or missing information, and resolving issues by updating records in NBSS before uploading the data to the Breast Screening System Information System (BSIS
This document provides an update on the Infectious Diseases in Pregnancy Screening (IDPS) Programme in the UK. It discusses the aims of the programme, which include enabling early detection and treatment of infections in pregnancy to reduce mother-to-child transmission. It summarizes screening activity data which shows high uptake rates of over 99% for HIV, hepatitis B, and syphilis screening. It also discusses efforts to improve laboratory quality, establish screening standards and outcomes data, and provide education resources to professionals and the public. Specific updates are provided on actions relating to HIV, syphilis, hepatitis B, and developing seamless maternal and neonatal pathways between screening and immunization programs.
10. Siobhan O'callaghan findings from QA activitiesPHEScreening
The QA advisor summarizes findings from 30 QA visits reports between September 2017 and July 2018. A total of 786 QA recommendations were made across various themes. The top theme was infectious diseases in pregnancy, receiving 218 recommendations. Of these, 61 recommendations were specific to the laboratory, focusing on issues like properly identifying and tracking antenatal samples, notifying screening results, and ensuring UKAS accreditation. Generic recommendations that appeared across themes included formalizing governance, managing incidents, and meeting standards for staff training and turnaround times.
9. Judith Timms HIV screening incidentsPHEScreening
This document discusses false positive HIV results that can occur during HIV screening. The main causes of false positives are wrong blood in the tube or laboratory error. Laboratory error is found to be the most common cause, responsible for false positives in 8 of 9 cases reviewed from 2014 to 2017. Specific cases of laboratory errors are presented, including possible contamination during automated testing processes and issues with old laboratory equipment. The implications of false positive results, such as distress to patients, are also covered.
8. Nadia Permalloo learning from incidentsPHEScreening
This document summarizes themes from quarterly incident reports of a screening program covering October 2015 to December 2017. Key issues identified include screening without informed consent, insufficient samples not being repeated in a timely manner, tracking and communication failures leading to unreported positive screening results, delays when using reference laboratories, and unconfirmed screening results being communicated to patients. The document concludes with a checklist of questions around improving processes to address these issues.
7. Tom Lewis Getting it right for pathology presentationPHEScreening
This document summarizes a presentation on the Getting It Right First Time (GIRFT) program and its workstream focused on pathology. GIRFT aims to reduce unwarranted variation in clinical care through data collection, identifying best practices, and promoting changes. The pathology workstream is led by four clinical leads and aims to measure current variability in pathology services, create a vision for the future, and test changes. Key activities will include collecting data through questionnaires and site visits to understand variations and identify opportunities for improvement.
6. Madeline McMahon IDPS workshop 13 march v2.0PHEScreening
The document discusses standards for infectious disease screening in pregnancy. It outlines 7 standards for screening coverage and test turnaround time. Standard 4 focuses on the test turnaround time for HIV, hepatitis B, and syphilis screening, requiring results be reported within 8 working days of sample receipt. Performance is tracked by region. Common issues with submitting data are outlined, and a proposed change to the submission template is presented to help clarify reporting of pending or inconclusive results. Laboratories are responsible for submitting Standard 4 data to maternity services by the end of June for the previous year's reporting period.
R3 Stem Cell Therapy: A New Hope for Women with Ovarian FailureR3 Stem Cell
Discover the groundbreaking advancements in stem cell therapy by R3 Stem Cell, offering new hope for women with ovarian failure. This innovative treatment aims to restore ovarian function, improve fertility, and enhance overall well-being, revolutionizing reproductive health for women worldwide.
COPD Treatment in Ghatkopar,Mumbai. Dr Kumar DoshiDr Kumar Doshi
Are you or a loved one affected by Chronic Obstructive Pulmonary Disease (COPD)? Discover comprehensive and advanced treatment options with Dr. Kumar Doshi, a preeminent COPD specialist based in Ghatkopar, Mumbai.
Dr. Kumar Doshi is dedicated to delivering the highest standard of care for COPD patients. Whether you are seeking a diagnosis, a second opinion, or exploring new treatment avenues, this presentation will guide you through the exceptional services available at his practice in Ghatkopar, Mumbai.
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Ear Solutions (ESPL)
Binaural hearing using two hearing aids instead of one offers numerous advantages, including improved sound localization, enhanced sound quality, better speech understanding in noise, reduced listening effort, and greater overall satisfaction. By leveraging the brain’s natural ability to process sound from both ears, binaural hearing aids provide a more balanced, clear, and comfortable hearing experience. If you or a loved one is considering hearing aids, consult with a hearing care professional at Ear Solutions hearing aid clinic in Mumbai to explore the benefits of binaural hearing and determine the best solution for your hearing needs. Embracing binaural hearing can lead to a richer, more engaging auditory experience and significantly improve your quality of life.
Get Covid Testing at Fit to Fly PCR TestNX Healthcare
A Fit-to-Fly PCR Test is a crucial service for travelers needing to meet the entry requirements of various countries or airlines. This test involves a polymerase chain reaction (PCR) test for COVID-19, which is considered the gold standard for detecting active infections. At our travel clinic in Leeds, we offer fast and reliable Fit to Fly PCR testing, providing you with an official certificate verifying your negative COVID-19 status. Our process is designed for convenience and accuracy, with quick turnaround times to ensure you receive your results and certificate in time for your departure. Trust our professional and experienced medical team to help you travel safely and compliantly, giving you peace of mind for your journey.
International Cancer Survivors Day is celebrated during June, placing the spotlight not only on cancer survivors, but also their caregivers.
CANSA has compiled a list of tips and guidelines of support:
https://cansa.org.za/who-cares-for-cancer-patients-caregivers/
We are one of the top Massage Spa Ajman Our highly skilled, experienced, and certified massage therapists from different corners of the world are committed to serving you with a soothing and relaxing experience. Luxuriate yourself at our spas in Sharjah and Ajman, which are indeed enriched with an ambiance of relaxation and tranquility. We could confidently claim that we are one of the most affordable Spa Ajman and Sharjah as well, where you can book the massage session of your choice for just 99 AED at any time as we are open 24 hours a day, 7 days a week.
Visit : https://massagespaajman.com/
Call : 052 987 1315
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Gemma Wean- Nutritional solution for Artemiasmuskaan0008
GEMMA Wean is a high end larval co-feeding and weaning diet aimed at Artemia optimisation and is fortified with a high level of proteins and phospholipids. GEMMA Wean provides the early weaned juveniles with dedicated fish nutrition and is an ideal follow on from GEMMA Micro or Artemia.
GEMMA Wean has an optimised nutritional balance and physical quality so that it flows more freely and spreads readily on the water surface. The balance of phospholipid classes to- gether with the production technology based on a low temperature extrusion process improve the physical aspect of the pellets while still retaining the high phospholipid content.
GEMMA Wean is available in 0.1mm, 0.2mm and 0.3mm. There is also a 0.5mm micro-pellet, GEMMA Wean Diamond, which covers the early nursery stage from post-weaning to pre-growing.
The facial nerve, also known as cranial nerve VII, is one of the 12 cranial nerves originating from the brain. It's a mixed nerve, meaning it contains both sensory and motor fibres, and it plays a crucial role in controlling various facial muscles, as well as conveying sensory information from the taste buds on the anterior two-thirds of the tongue.
1. Is AAAscreening an opportunity to
screen for other cardiovascular
disease?
Matt Bown, Professor of Vascular Surgery, Director of Clinical
Academic Training, College of Life Sciences, University of
Leicester
2. Is AAA screening an opportunity to screen for
other cardiovascular disease?
Matt Bown
University of Leicester
www.le.ac.uk
8. Research proposal
Does the addition of screening for peripheral arterial
disease to AAA screening improve the health of men
invited for screening?
What is the best screening test for PAD?
How do we add PAD screening to AAA screening?
How might we run a trial in NAAASP?
10. Project plan
1. Select a screening tool
2. Test acceptability and accuracy
3. Small scale feasibility study of PAD+AAA screening
4. Multi-centre randomized trial of PAD+AAA screening
11. Project plan
1. Select a screening tool
2. Test acceptability and accuracy
3. Small scale feasibility study of PAD+AAA screening
4. Multi-centre randomized trial of PAD+AAA screening
12. Sample size consideration
• Outcome: cardiovascular events/deaths.
• 19% at 5 years in men invited for AAA screening
• Intervention may have small effects
• Need to randomize around 50,000 to 90,000 men
13. Trial design options
• Individual randomization
• Group randomization
– GP practices
– CCGs
– NAAASP units
28. Other options
NAAASP
Unit 1
NAAASP
Unit 2
NAAASP
Unit 3
Year/quarter
1
Year/quarter
2
Year/quarter
3
Year/quarter
4
AAA AAA AAA PAD+AAA
AAA
AAA
PAD+AAA PAD+AAA PAD+AAA
PAD+AAAAAA PAD+AAA
29. What schema is most acceptable/practical?
• Individual randomization:
– Even chance for all men
– All units involved
– Less impact on individual clinics?
• Group randomization
– Less waiting room contamination?
– Easier to organize?
• GP vs CCG vs NAAASP unit
– Some units may not get to do new methods